Dilution

[키워드] 95% CI Action Analysis antibody baseline COVID-19 COVID-19-related symptom cycle threshold defined Dilution domain effective ELISA enrolled Follow-up full-length spike protein groups hazard ratio healthy home quarantine hotel IgG Immunity incidence rate individuals infected with SARS-CoV-2 Infection infection risk information initial investigated island male mass vaccination medical history men neutralisation activity neutralising neutralising antibody titre observation ORF1 ORF1ab gene participant Participants PCR PCR test person-year positive positive PCR test prospective cohort study Prospective Study Protective quarantine Quarantine period question questionnaire rate ratio Receptor-binding domain response risk Risk factors SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection selected serology test seronegative seronegative participant seronegative participants seropositive seropositive participant seropositive participants Seropositivity serum Spike protein study visit subsequent Swab Symptom tested titre uninfected uninfected participant Vaccination strategies Viral Viral load viral loads was performed were assessed were excluded
[DOI] 10.1016/S2213-2600(21)00158-2 PMC 바로가기 [Article Type] Article